Cetuximab: Difference between revisions
imported>Robert Badgett (New page: In medicine, '''cetuximab''' (se tux' i mab) is "an antibody that blocks receptors for epidermal growth factor."<ref>{{MeSH}}</ref> ==Referen...) |
Pat Palmer (talk | contribs) (fixing refs) |
||
| (3 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
In [[medicine]], '''cetuximab''' (se tux' i mab) is "an antibody that blocks [[epidermal | {{subpages}} | ||
{{TOC|right}} | |||
In [[medicine]], '''cetuximab''' (se tux' i mab) is an [[antineoplastic agent]] that is "an [[antibody]] that blocks [[epidermal growth factor receptor|receptors]] for [[epidermal growth factor]]."<ref>{{MeSH}}</ref> | |||
==Uses== | |||
===Head and neck cancer=== | |||
Cetuximab can help treat [[head and neck cancer]]; the percentage of cells that are EGFR positive did not seen to predict the response to cetuximab in a [[randomized controlled trial]].<ref name="pmid18784101">{{cite journal| author=Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al.| title=Platinum-based chemotherapy plus cetuximab in head and neck cancer. | journal=N Engl J Med | year= 2008 | volume= 359 | issue= 11 | pages= 1116-27 | pmid=18784101 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=18784101 | doi=10.1056/NEJMoa0802656 }} </ref> | |||
===Colorectal cancer=== | |||
Cetuximab can help treat [[colorectal cancer]] in patients whose cancer expressed [[epidermal growth factor receptor]] according to a [[randomized controlled trial]].<ref name="pmid18003960">{{cite journal |author=Jonker DJ, O'Callaghan CJ, Karapetis CS, ''et al'' |title=Cetuximab for the treatment of colorectal cancer |journal=N. Engl. J. Med. |volume=357 |issue=20 |pages=2040–8 |year=2007 |pmid=18003960 |doi=10.1056/NEJMoa071834}}</ref> This trial did not include patients whose cancers did not express [epidermal growth factor receptor]]. | |||
==Drug toxicity== | |||
[[Drug toxicity]] includes a acneiform papulopustular rash involving the face and trunk in about 10% of patients.<ref name="pmid18003960"/><ref name="pmid18784101"/> In patients with colorectal cancer<ref name="pmid18003960"/>, but not head and neck cancer<ref name="pmid18784101"/>, this rash is associated with improved survival. | |||
==References== | ==References== | ||
<small> | |||
<references/> | <references/> | ||
</small> | |||
Latest revision as of 10:15, 13 September 2024
In medicine, cetuximab (se tux' i mab) is an antineoplastic agent that is "an antibody that blocks receptors for epidermal growth factor."[1]
Uses
Head and neck cancer
Cetuximab can help treat head and neck cancer; the percentage of cells that are EGFR positive did not seen to predict the response to cetuximab in a randomized controlled trial.[2]
Colorectal cancer
Cetuximab can help treat colorectal cancer in patients whose cancer expressed epidermal growth factor receptor according to a randomized controlled trial.[3] This trial did not include patients whose cancers did not express [epidermal growth factor receptor]].
Drug toxicity
Drug toxicity includes a acneiform papulopustular rash involving the face and trunk in about 10% of patients.[3][2] In patients with colorectal cancer[3], but not head and neck cancer[2], this rash is associated with improved survival.
References
- ↑ Anonymous (2024), Cetuximab (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ 2.0 2.1 2.2 Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al. (2008). "Platinum-based chemotherapy plus cetuximab in head and neck cancer.". N Engl J Med 359 (11): 1116-27. DOI:10.1056/NEJMoa0802656. PMID 18784101. Research Blogging.
- ↑ 3.0 3.1 3.2 Jonker DJ, O'Callaghan CJ, Karapetis CS, et al (2007). "Cetuximab for the treatment of colorectal cancer". N. Engl. J. Med. 357 (20): 2040–8. DOI:10.1056/NEJMoa071834. PMID 18003960. Research Blogging.